400 related articles for article (PubMed ID: 28053335)
21. Assessment of Availability, Clinical Testing, and US Food and Drug Administration Review of Biosimilar Biologic Products.
Moore TJ; Mouslim MC; Blunt JL; Alexander GC; Shermock KM
JAMA Intern Med; 2021 Jan; 181(1):52-60. PubMed ID: 33031559
[TBL] [Abstract][Full Text] [Related]
22. Addressing unmet clinical needs: the potential of biosimilars in the treatment of rheumatic diseases.
Schulze-Koops H
Rheumatology (Oxford); 2017 Aug; 56(suppl_4):iv1-iv3. PubMed ID: 28903541
[No Abstract] [Full Text] [Related]
23. Biosimilars in rheumatology: recommendations for regulation and use in Middle Eastern countries.
El Zorkany B; Al Ani N; Al Emadi S; Al Saleh J; Uthman I; El Dershaby Y; Mounir M; Al Moallim H
Clin Rheumatol; 2018 May; 37(5):1143-1152. PubMed ID: 29411181
[TBL] [Abstract][Full Text] [Related]
24. Global regulatory standards for the approval of biosimilars.
Mounho B; Phillips A; Holcombe K; Grampp G; Lubiniecki T; Mollerup I; Jones C
Food Drug Law J; 2010; 65(4):819-37, ii-iii. PubMed ID: 24479248
[TBL] [Abstract][Full Text] [Related]
25. Biosimilars in pediatric rheumatology and their introduction into routine care.
Aragon Cuevas O; Hedrich CM
Clin Immunol; 2020 Jul; 216():108447. PubMed ID: 32360950
[TBL] [Abstract][Full Text] [Related]
26. The advent of biosimilar therapies in rheumatology--"O brave new world".
Scheinberg MA; Kay J
Nat Rev Rheumatol; 2012 Jun; 8(7):430-6. PubMed ID: 22664834
[TBL] [Abstract][Full Text] [Related]
27. US rheumatologists' beliefs and knowledge about biosimilars: a survey.
Gibofsky A; McCabe D
Rheumatology (Oxford); 2021 Feb; 60(2):896-901. PubMed ID: 33146388
[TBL] [Abstract][Full Text] [Related]
28. Biosimilar drugs in Mexico: position of the Mexican College of Rheumatology, 2012.
Espinosa Morales R; Díaz Borjón A; Barile Fabris LA; Esquivel Valerio JA; Medrano Ramírez G; Arce Salinas CA; Barreira Mercado ER; Cardiel Ríos MH; Díaz Jouanen E; Flores Murrieta FJ; Fraga Mouret A; Garza Elizondo MA; Luján Estrada M; Muñoz Barradas FJ; Talavera Piña JO; Vera Lastra OL;
Reumatol Clin; 2013; 9(2):113-6. PubMed ID: 23395225
[TBL] [Abstract][Full Text] [Related]
29. Biosimilar monoclonal antibodies: preclinical and clinical development aspects.
Gonçalves J; Araújo F; Cutolo M; Fonseca JE
Clin Exp Rheumatol; 2016; 34(4):698-705. PubMed ID: 27383278
[TBL] [Abstract][Full Text] [Related]
30. Position paper of Italian rheumatologists on the use of biosimilar drugs.
Atzeni F; Sebastiani M; Ricci C; Celano A; Gremese E; Iannone F; Meroni PL; Minghetti P; Sarzi-Puttini P; Ferraccioli G; Lapadula G
Clin Exp Rheumatol; 2015; 33(1):1-4. PubMed ID: 25436597
[TBL] [Abstract][Full Text] [Related]
31. Biosimilars: Rationale and current regulatory landscape.
Olech E
Semin Arthritis Rheum; 2016 Apr; 45(5 Suppl):S1-10. PubMed ID: 26947438
[TBL] [Abstract][Full Text] [Related]
32. Biosimilars: The US Regulatory Framework.
Christl LA; Woodcock J; Kozlowski S
Annu Rev Med; 2017 Jan; 68():243-254. PubMed ID: 27813877
[TBL] [Abstract][Full Text] [Related]
33. Foreword: Follow-on Biologics: Implementation Challenges and Opportunities.
Paradise J
Seton Hall Law Rev; 2011; 41(2):501-10. PubMed ID: 21739728
[TBL] [Abstract][Full Text] [Related]
34. Utilizing data consortia to monitor safety and effectiveness of biosimilars and their innovator products.
; Baldziki M; Brown J; Chan H; Cheetham TC; Conn T; Daniel GW; Hendrickson M; Hilbrich L; Johnson A; Miller SB; Moore T; Motheral B; Priddy SA; Raebel MA; Randhawa G; Surratt P; Walraven C; White TJ; Bruns K; Carden MJ; Dragovich C; Eichelberger B; Rosato E; Sega T
J Manag Care Spec Pharm; 2015 Jan; 21(1):23-34. PubMed ID: 25562770
[TBL] [Abstract][Full Text] [Related]
35. Anti-tumor necrosis factor biosimilars and intended copies in rheumatology: Perspective from the Asia Pacific region.
Rath PD; Chen DY; Gu J; Lee VWY; Al Ani NA; Shirazy K; Llamado L
Int J Rheum Dis; 2019 Jan; 22(1):9-24. PubMed ID: 30338644
[TBL] [Abstract][Full Text] [Related]
36. Clinical and regulatory perspectives on biosimilar therapies and intended copies of biologics in rheumatology.
Mysler E; Pineda C; Horiuchi T; Singh E; Mahgoub E; Coindreau J; Jacobs I
Rheumatol Int; 2016 May; 36(5):613-25. PubMed ID: 26920148
[TBL] [Abstract][Full Text] [Related]
37. Biosimilars in rheumatology: current perspectives and lessons learnt.
Dörner T; Kay J
Nat Rev Rheumatol; 2015 Dec; 11(12):713-24. PubMed ID: 26282080
[TBL] [Abstract][Full Text] [Related]
38. Progress in biosimilar monoclonal antibody development: the infliximab biosimilar CT-P13 in the treatment of rheumatic diseases.
Braun J; Kudrin A
Immunotherapy; 2015; 7(2):73-87. PubMed ID: 25713985
[TBL] [Abstract][Full Text] [Related]
39. Update on biosimilars in rheumatology.
Rischin A; Östör AJ
Inflammopharmacology; 2017 Apr; 25(2):177-184. PubMed ID: 28265837
[TBL] [Abstract][Full Text] [Related]
40. Biosimilars: biologics that meet patients' needs and healthcare economics.
McCamish M; Yoon W; McKay J
Am J Manag Care; 2016 Sep; 22(13 Suppl):S439-S442. PubMed ID: 28719221
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
